Course Summary
Contact Hour(s):
3 Contact Hours
Contact hours for LPNs in any state are earned by completing this course. This is part of a series of 24 contact hours of courses to prepare for LPN IV Certification in Florida. Florida certification participants must schedule a 6-hour live presentation and return demonstration to complete IV Certification. The live presentation is not provided by CEUFast.com.
Author:
Desiree Reinken, PhD, APRN, NP-C
Julia Tortorice, RN, MBA, MSN, EdD, NEA
This peer-reviewed course is applicable for the following professions:
Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Registered Nurse (RN)
Accreditations:
The American Nurses Credentialing Center (ANCC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353
Course Description:
This course introduces administering blood and blood products. The blood components, including red and white blood cells, are discussed. The types of blood, both common and uncommon, are reviewed. Different types of blood transfusions, including alternatives to blood transfusions, are outlined. Blood compatibility, including specific procedures and tests, is examined. Along with the benefits of blood transfusions, the risks of transfusion are also discussed.
Outcomes:
≥92% of LPNs will be qualified to administer blood products safely.
Objectives:
Upon completion of this course, the participant will be able to:
- Distinguish between the different components of blood.
- Summarize various blood types.
- Evaluate different types of blood transfusions.
- Compare different types of alternatives to blood transfusions.
- Identify the risks of blood transfusions.
- Outline procedures to reduce the risk of blood transfusion reactions.
- Examine the essential steps to safely administer blood and blood products.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.